{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-003248","form_type":"8-K","ticker":null,"cik":"0001661460","company_name":"Poseida Therapeutics, Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.352593+00:00","generated_at":"2026-05-28T06:49:36.267774+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Roche completes acquisition of Poseida Therapeutics for $9.00/share plus contingent value rights","bullets":["Tender offer expired Jan 7, 2025; 66.11% of shares tendered, with an additional 8.01% via guaranteed delivery.","Merger closed Jan 8, 2025; shareholders receive $9.00 per share cash plus CVRs up to $4.00 per share.","Poseida becomes a wholly owned subsidiary of Roche Holdings; stock to be delisted from Nasdaq.","Board and officers replaced by Roche appointees; Mark Gergen resigned as officer with severance.","Loan agreement with Oxford Finance LLC terminated and fully repaid in connection with the merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-003248","json":"https://secwatch.observer/filing/0001193125-25-003248.json","markdown":"https://secwatch.observer/filing/0001193125-25-003248.md","text":"https://secwatch.observer/filing/0001193125-25-003248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/d874651d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:49:36.267774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18f58c1c6b","claim":"John Schmid resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2a573c15f8","claim":"Mark Gergen resigned as other_named_officer at Poseida Therapeutics, Inc..","evidence_excerpt":"Mark Gergen resigned as an officer and separated from employment with the Company effective as of immediately following the Effective Time","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"76fc77e48d","claim":"Rafael Amado resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7f7d60973f","claim":"Marcea Lloyd resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"911d6def2a","claim":"Luke Corning resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"953819300d","claim":"Roger Brown was appointed as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"the directors of Merger Sub as of immediately prior to the Effective Time, Sean A. Johnston and Roger Brown, became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9b521573ef","claim":"Sean A. Johnston was appointed as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"the directors of Merger Sub as of immediately prior to the Effective Time, Sean A. Johnston and Roger Brown, became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9cfb43f44b","claim":"Mark Gergen resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a4efa06c7f","claim":"Cynthia Collins resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b34c0a3406","claim":"Kristin Yarema resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dbaab30add","claim":"Charles Baum resigned as Director at Poseida Therapeutics, Inc..","evidence_excerpt":"each of Rafael Amado, Charles Baum, Cynthia Collins, Luke Corning, Mark Gergen, Marcea Lloyd, John Schmid and Kristin Yarema voluntarily resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"589448c086004632f379da3ca151f14677258d5b","claim":"Poseida Therapeutics, Inc.: Certificate of incorporation and bylaws amended and restated in connection with a merger.","evidence_excerpt":"the Company's certificate of incorporation and bylaws were amended and restated in their entirety in the forms filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.4,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"1332d1ebb11ae3357939f0d7c8ff50a11454de58","claim":"Poseida Therapeutics, Inc. underwent a change of control involving Roche Holdings, Inc. and Blue Giant Acquisition Corp. for $9.00 per Share plus one contingent value right per Share (closed 2025-01-08).","evidence_excerpt":"(“ Parent ”) and Blue Giant Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”). Pursuant to the Merger Agreement, on December 9, 2024, Merger Sub commenced a tender offer to acquire all of the issued and outstanding shares (the “ Shares ”) of common stock, par value $0.0001 per share (the “ Company Common","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/0001193125-25-003248-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Roche Holdings, Inc. and Blue Giant Acquisition Corp."},{"label":"Consideration","value":"$9.00 per Share plus one contingent value right per Share"},{"label":"Closing","value":"2025-01-08"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}